NEET MDS 2024: Here Are Top 10 NIRF-Ranked Dental Colleges In India

New Delhi- The National Eligibility and Entrance Test for Masters of Dental Surgery, also known as NEET MDS, was held on March 18, 2024. NEET-MDS is an eligibility-cum-ranking test prescribed as a single entrance test for admission to various MDS courses.

No other entrance examination at the state or institution level will be valid for admission to MDS courses. Candidates have to qualify the NEET-MDS for admission to MDS courses under various universities/institutions in the country.

Every year lakhs of interested students eagerly wait for this examination. Along with this, students also look for top-ranked dental colleges in India.

Here is the list of the top 10 dental colleges in India ranked by the National Institutional Ranking Framework (NIRF) with cut-off percentages-

NIRF RANK

NAME OF THE INSTITUTE

STATE

1

Name of the Institute

Chennai, Tamil Nadu

2

Manipal College of Dental Sciences, Manipal

Manipal, Karnataka

3

Dr. D. Y. Patil Vidyapeeth

Pune, Maharashtra

4

Maulana Azad Institute of Dental Sciences

Delhi, Delhi

5

A.B.Shetty Memorial Institute of Dental Sciences

Mangaluru, Karnataka

6

SRM Dental College

Chennai, Tamil Nadu

7

Sri Ramachandra Institute of Higher Education and Research

Chennai, Tamil Nadu

8

Manipal College of Dental Sciences, Mangalore

Mangalore, Karnataka

9

Siksha `O` Anusandhan

Bhubaneswar, Odisha

10

Jamia Millia Islamia, New Delhi

New Delhi, Delhi

These top 10 ranked medical colleges help students get an exceptional medical education and potentially bright career prospects.

Meanwhile, the minimum qualifying percentage cutoff for NEET MDS 2023 last year, as determined by the NBE, is 50% for the General and EWS categories, 40% for SC, ST, OBC and Reserved PWD categories and 45% for the General PWD/EWS PWD category. The cutoff in all categories had been reduced by 31.807 per cent.

NEET MDS is conducted by the National Board of Examination in Medical Sciences (NBEMS) on March 18, 2024, despite requests for rescheduling and the Supreme Court rejecting the stay petition. Medical Dialogues had earlier reported that MDS aspirants had approached the Supreme Court seeking postponement of the exam and an extension of the deadline to complete the BDS internship. However, the NEET MDS 2024 exam did not get rescheduled, issuing a notice in this regard, the National Board of Examinations (NBE) confirmed that the exam would be conducted on its scheduled date i.e. on 18th March 2024. Meanwhile, based on the directions issued by the Union Health Ministry, NBEMS extended the deadline for completion of the BDS internship till 30th June 2024.

The result is scheduled to be released on 18th April 2024.

Powered by WPeMatico

Study finds e-cigarette users now more likely to quit traditional cigarettes

A new paper in Nicotine & Tobacco Research finds that smokers who switch to electronic cigarettes are now more likely to stop smoking regular cigarettes. In the past, smokers who began using electronic cigarettes mostly continued smoking. The paper is titled, “Divergence in cigarette discontinuation rates by use of electronic nicotine delivery systems (ENDS): Longitudinal findings from the U.S. PATH Study Waves 1-6.”

Powered by WPeMatico

A paramedic was skeptical about this treatment for stopping repeat opioid overdoses. Then he saw it help

Fire Capt. Jesse Blaire steered his SUV through the mobile home park until he spotted the little beige house with white trim and radioed to let dispatchers know he’d arrived.

Powered by WPeMatico

Doctors on front line of tackling childhood obesity need more training and resources, say researchers

Doctors are feeling unable to tackle the growing problem of childhood obesity due to a lack of training and capacity according to new research.

Powered by WPeMatico

New report presents a global plan to combat prostate cancer

Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% to almost 700,000 over the same timeframe—mainly among men in low- and middle-income countries. A commissioned report published in The Lancet highlights the future landscape of prostate cancer and seeks to guide cancer experts worldwide on how to manage the massive influx of prostate cancer patients projected over the next two decades.

Powered by WPeMatico

Gut bacteria that strongly influence obesity are different in men and women, study finds

New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12–15 May) identifies changes in the composition of gut bacteria that may play a key role in the onset and development of obesity, with differences in men and women, which might affect the metabolism of different nutrients and therefore the presence of bioactive molecules in the gut that influence the development of metabolic disease.

Powered by WPeMatico

Abbott gets USFDA approval for TriClip TEER System for Tricuspid Regurgitation

Abbott Park, III.: Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first-of-its-kind TriClip transcatheter edge-to-edge repair (TEER) system that’s specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve.

This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefits of TriClip outweighed the risks.

“The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues,” said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE Pivotal trial. “With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker.”

The tricuspid valve controls blood as it flows from the heart’s right atrium to the right ventricle. TR occurs when the valve doesn’t close properly, causing a leak and allowing blood to flow backward in the heart. TR can force the heart to work harder, causing debilitating symptoms such as fatigue and shortness of breath. When left untreated, TR can lead to atrial fibrillation, heart failure, and ultimately, death. For those who continue to have symptoms or persistent TR despite treatment with medical therapy and are not considered good candidates for surgery, TriClip represents an option that can improve a person’s quality of life.

Delivered through a vein in the leg, TriClip’s TEER technology works by clipping together a portion of the leaflets – or flaps of tissue – to repair the tricuspid valve and help blood flow in the right direction without the need for open-heart surgery. On average, people who receive TriClip only need one day in the hospital before they recover and can return home.

As part of its approval process, the FDA reviewed findings from the TRILUMINATE Pivotal trial, the world’s first randomized, controlled clinical study to evaluate the safety and effectiveness of the TriClip system compared to medical therapy in people with severe TR who are at intermediate or greater risk for open-heart surgery. In the study, 90% of patients who received the TriClip system experienced a marked improvement in their TR grade, reducing from severe or higher to moderate or less at 30 days – a reduction that was sustained at one year. The trial also demonstrated a highly favorable safety profile, with 98% of patients being free of major adverse events through 30 days, and a significant improvement in quality of life.

“This approval helps address a treatment gap for people with tricuspid regurgitation who previously had few options to treat a disease that adversely impacted their daily lives and could lead to other deadly conditions,” said Sandra Lesenfants, senior vice president of Abbott’s structural heart business. “With the addition of TriClip to our broad structural heart therapy offerings in the U.S., we are continuing to bring meaningful, life-enhancing benefits to patients with cardiovascular conditions.”

TriClip leverages the same clip-based technology as Abbott’s MitraClip device – which has treated more than 200,000 people with leaky mitral valves (mitral regurgitation) – but was specifically designed to treat the tricuspid valve’s complex anatomy.

TriClip has been approved for use in more than 50 countries, including in Europe and Canada, since its initial CE Mark approval in 2020. The device has already been used to treat more than 10,000 people with TR.

In addition to TriClip, the company’s minimally invasive therapies include first-of-its-kind technologies MitraClip and Amplatzer Piccolo Occluder (to close a hole in the heart of babies), as well as the Navitor transcatheter aortic valve implantation system (to treat aortic stenosis). 

Read also: Abbott gets USFDA clearance for whole blood rapid test to help with assessment of concussion at patient bedside

Powered by WPeMatico

Maharashtra Govt consolidates hospital bed capacities to advance proposal for new Medical College

Mumbai: In a significant move aimed at advancing the approval process for a new 100-seat medical college, the state has consolidated the bed capacities of two prominent hospitals, GT Hospital in Dhobi Talao and Cama and Albless Hospital in Fort. It will increase the number of beds to 1,026 beds.

This consolidation came
as part of the state government’s efforts to revive a proposal, dormant since
2011, to establish a new medical college at GT Hospital. The proposal gained
momentum last November. The initial plan was to offer MBBS degrees and later it
was expanded to post-graduate and specialized programs.

Under the revised plan, the renowned JJ Group of Hospitals will oversee only two hospitals, JJ Hospital and St George. At the same time, GT Hospital and Cama and Albless will function as a separate entity. Dr Jeetendra Sankpal, a famous surgeon, has been appointed as the dean of the proposed institute, tentatively named Government Medical College, Mumbai. The institute is poised to commence operations from Cama and Albless for the first two years, reports The Times of India.

The inspection by the National Medical Commission is pending but it might take place any day now. “Campuses of both these hospitals are being spruced for the NMC inspection,” said an official. Explaining the rationale behind this decision, Dr Sankpal cited the availability of more lecture rooms at Cama & Albless, which aligns with the non-clinical focus of the initial two years of the curriculum. “The initial two years are mostly focussed on non-clinical cases, so the classes can be conducted from Cama, Later as clinical subjects are initiated, the classes will be conducted from GT Hospital,” said Dr Sankpal. As the institute progresses to clinical subjects, classes will transition to GT Hospital, reports The Daily.

Officials from the medical education department have confirmed that hostel spaces for students have been identified in GT Hospital. Addressing the infrastructure concerns, a state official stated that there would be a window of 3-4 years to develop the necessary infrastructure, during which the facilities at GT and Cama hospitals should be adequate. The official said they are hopeful that the faculty from GT and Cama will suffice to get permission for the new college. However, the college would still require a building of its own. 

Also Read: Fortis Hospital Mulund unveils The First Movement Disorder and DBS Clinic

Powered by WPeMatico

NBE Invites Applications for DNB, DrNB Final Theory Exams May 2024, all details here

New Delhi- The National Board of Examination in Medical Sciences (NBEMS) has invited applications for the DNB and DrNB Final Theory Examinations scheduled for May 2024. In this regard, NBE has issued an information bulletin detailing the eligibility criteria, fee structure, scheme of examination and other details.

This DNB and DRNB Final Theory Examination for May 2024 will be conducted on 15, 16, 17 and 18 May 2024 at various examination centres across the country. Candidates can submit applications for the said examination online from 2 April 2024 (3 PM onwards) to 22 April 2024 (11:55 PM onwards).

HOW TO FILL APPLICATION FORM

1 Applicants have to register themselves online on the Online Exit Examination Portal (OEEP) to submit the DNB/DRNB Final Examination application to the National Board of Examination in Medical Sciences. The online exit examination portal can be accessed through the official website of NBEMS.

2 After successful registration and application submission, candidates can log in to their OEEP account to check the status of the online application submitted for DNB/DRNB final examinations, any deficiencies will inform them about downloading the admit card.

3 Application for DNB/DRNB Final Theory Examination- May 2024 can be submitted online only through the official website of the National Board of Examination in Medical Sciences. There is no other mode of submission of application and if it is submitted through any other mode it will be summarily rejected.

4 Following steps shall be required to be completed in sequence for application submission to NBEMS:

A. Register a User.

B. Complete the Application form, Examination City Selection and Upload Prescribed Documents.

C. Pay Examination Fee.

5 The applicant candidate shall register a username and create his/her online profile with the Online Exit Examinations Portal. On successful creation of the candidate profile, the applicant shall be required to complete the DNB/DrNB Final Examinations application form, pay the prescribed examination fee and upload the prescribed documents online. Candidates shall be able to preview the application form for any corrections required before final submission.

6 The applicant candidate may save and print the application form submitted online for future reference. There is no requirement to submit the hard copy of the application form and documents uploaded to NBEMS.

TIME TABLE OF DNB FINAL (BROAD SPECIALITY)

Paper

Day

Date

Exam Time

I

Wednesday

15.05.2024

2:00 PM-5:00 PM

II

Thursday

16.05.2024

2:00 PM-5:00 PM

III

Friday

17.05.2024

2:00 PM-5:00 PM

IV

Saturday

18.05.2024

2:00 PM-5:00 PM

TIME TABLE OF DrNB FINAL (SUPER SPECIALITY)

Paper

Day

Date

Exam Time

I

Wednesday

15.05.2024

2:00 PM-5:00 PM

II

Thursday

16.05.2024

2:00 PM-5:00 PM

III

Friday

17.05.2024

2:00 PM-5:00 PM

TIME TABLE OF SUPER SPECIALITY DIRECT 6 YEARS COURSE-PART-I

Paper

Day

Date

Exam Time

I

Wednesday

15.05.2024

2:00 PM-5:00 PM

II

Thursday

16.05.2024

2:00 PM-5:00 PM

EXAMINATION FEE

Candidate

Examination Fee (Theory & Practical)

Registration Fee

Total* (in Rs.)

DNB/DrNB Trainees

5250

Not Applicable#

5250

MD/MS or DM/MCh

5250

1000

6250

Only Practical Examination (DNB/DrNB trainee or MD/MS/DM/MCh Candidate)

5250

ELIGIBILITY CRITERIA OF DNB BROAD SPECIALITY

1 Candidates who have undergone training as a DNB trainee at any of the National Board of Examinations in Medical Sciences accredited institutes after having registered with NBEMS as a DNB trainee and are completing their prescribed training as a DNB trainee by the date mentioned below & on submission of a certificate to this effect, can undertake the DNB Final Examination in the same speciality.

2 Submission of Training Completion Certificate indicating details of leave taken during DNB training for DNB trainees is an essential pre-requisite. In case the candidate does not submit the training Completion certificate along with the application form, his/her application shall be rejected and fees forfeited.

3 Request for extension in cutoff date for completion of training for eligibility determination for DNB final Examination shall not be considered.

4 Candidates who have completed their DNB training while applying for the DNB Final Examination shall be required to submit a Final Training Completion Certificate (FTCC).

5 Candidates whose DNB training is ongoing while applying for the DNB Final Examination shall be required to submit a Provisional Training Completion Certificate (PTCC). The PTCC must confirm that the candidate would be able to complete his/her training by the prescribed cut-off after taking into consideration all leave taken vis-a-vis the maximum permissible leave as per NBEMS leave rules and the required period of extension, if any. Such candidates are required to submit a Final Training Completion Certificate (FTCC) as per the format in Annexure-IV immediately upon completion of their training. Such candidates shall be provisionally allowed to appear for the DNB Final Examination subject to completion of their DNB training by the prescribed cut-off date.

6 Candidates who submit their Provisional TCC with correct leave details projecting their training completion on/before the prescribed cut-off date for the examination, happen to avail more leave after applying for the examination due to some unforeseen reasons which might take their training beyond the prescribed cutoff date, shall NOT be declared INELIGIBLE for the examination.

7 If such a candidate qualifies for the theory and practical examination, his/her Provisional Pass Certificate shall only be issued on completion of his/her DNB training and submission of Final TCC to this effect.

8 If such a candidate qualifies theory examination but fails to qualify for the practical examination, his/her candidature for the theory examination shall remain valid and he/she shall be allowed to appear in the next remaining attempt(s) of the practical examination, provided that he/she completes his/her DNB training before the next attempt of practical examination.

9 However, candidates who at any stage are found to have misrepresented/failed to disclose the complete details of leave taken by them, in their Provisional TCC, shall be declared INELIGIBLE on failing to complete their training on/before the prescribed cut-off date for the examination. Candidature of such candidates for the DNB Final Examination shall stand cancelled and the result, if any declared, shall be treated as null and void.

10 In terms of the NBEMS notice dated 26th November 2019, appearance in the minimum required numbers of Formative Assessment Tests (FATs) during the DNB/DrNB training shall be mandatory towards eligibility for appearing in DNB/DrNB Final Examinations. This compulsory participation in FATs shall apply to candidates who have joined their training in or after the July 2019 admission session.

ELIGIBILITY CRITERIA OF DrNB SUPER SPECIALITY

1 Candidates who have undergone training as a DrNB trainee at any of the National Board of Examinations in Medical Sciences accredited institutes after having registered with NBEMS as a DrNB trainee and are completing their prescribed training as a DrNB trainee by the date mentioned below, & on submission of a certificate to this effect, can undertake the DrNB Final Examination in the same speciality.

2 Submission of Training Completion Certificate indicating details of leave taken during DrNB training for DrNB trainees is an essential pre-requisite. In case the candidate does not submit the training Completion certificate along with the application form, his/her application shall be rejected and fees forfeited.

3 Request for extension in cutoff date for completion of training for eligibility determination for DrNB final Examination shall not be considered.

4 Candidates who have completed their DrNB training while applying for the DrNB Final Examination shall be required to submit a Final Training Completion Certificate (FTCC).

5 Candidates whose DrNB training is ongoing while applying for the DrNB Final Examination shall be required to submit a Provisional Training Completion Certificate (PTCC). The PTCC must confirm that the candidate would be able to complete his/her training by the prescribed cut-off after taking into consideration all leave taken vis-a-vis the maximum permissible leave as per NBEMS leave rules and the required period of extension, if any. Such candidates are required to submit a Final Training Completion Certificate (FTCC) as per the format in Annexure-IV immediately upon completion of their training. Such candidates shall be provisionally allowed to appear for the DrNB Final Examination subject to completion of their DrNB training by the prescribed cut-off date.

6 Candidates who submit their Provisional TCC with correct leave details projecting their training completion on/before the prescribed cut-off date for the examination, happen to avail more leave after applying for the examination due to some unforeseen reasons which might take their training beyond the prescribed cutoff date, shall NOT be declared INELIGIBLE for the examination.

7 If such a candidate qualifies for the theory and practical examination, his/her Provisional Pass Certificate shall only be issued on completion of his/her DrNB training and submission of Final TCC to this effect.

8 If such a candidate qualifies theory examination but fails to qualify for the practical examination, his/her candidature for the theory examination shall remain valid and he/she shall be allowed to appear in the next remaining attempt(s) of the practical examination, provided that he/she completes his/her DrNB training before the next attempt of practical examination.

9 However, candidates who at any stage are found to have misrepresented/failed to disclose the complete details of leave taken by them, in their Provisional TCC, shall be declared INELIGIBLE on failing to complete their training on/before the prescribed cut-off date for the examination. Candidature of such candidates for the DrNB Final Examination shall stand cancelled and the result, if any is declared, shall be treated as null and void.

10 In terms of the NBEMS notice dated 26th November 2019, appearance in a minimum required number of Formative Assessment Tests (FATs) during the DNB/DrNB training shall be mandatory towards eligibility for appearing in DNB/DrNB Final Examinations. This compulsory participation in FATs shall apply to candidates who have joined their training in or after the July 2019 admission session.

EXAMINATION SCHEME OF DNB BROAD SPECIALITY

1 The theory examination comprises of four papers, a maximum mark of 100 each.

2 There are 10 short notes of 10 marks each, in each of the papers.

3 The number of short notes and their respective marks weightage may vary in some subjects/some papers.

4 Maximum time permitted is 3 hours.

5 Candidate must score at least 200/400 in the aggregate of 4 papers to qualify the theory examination. Grace marks of up to 2% of maximum marks i.e. 8/400 shall be given only to the candidates falling in the zone of consideration i.e. securing between 192-199 marks out of 400. 6 Only those candidates who have qualified the theory examination are permitted to take the practical examination.

EXAMINATION SCHEME OF DrNB SUPER SPECIALITY

1 Maximum Marks: 300

2 The theory exam comprises of three question papers.

3 There are 10 short notes of 10 marks each in the question paper.

4 The number of short notes and their respective marks weightage may vary in some subjects/some papers.

5 Maximum time permitted is 3 hours for each question paper.

6 Candidate must score at least 50% of maximum marks to qualify the theory exam i.e. candidate scoring 150 or more marks out of 300 shall be declared ‘pass’ in the theory examination.

7 Candidate must score at least 150/300 in the aggregate of 3 papers to qualify the theory examination. Grace marks of up to 2% of maximum marks i.e. 6/300 shall be given only to the candidates falling in the zone of consideration i.e. securing between 144-149 marks out of 300. 8 Candidates who have qualified the theory examination are permitted to take up the practical examination.

To view the information Bulletin, click the link below

Powered by WPeMatico

10 Million ABHA IDs in Just 2 Years: Industry Experts Discuss the Role of Ayushman Bharat Digital Mission in Mankind Pharma’s Docflix Exclusive 5W1H Podcast

Mankind
Pharma’s OTT platform for healthcare professionals, Docflix, tackles the
transformative Ayushman Bharat Digital Mission (ABDM) in its recent episode of
the exclusive podcast series, 5W1H. The
episode features a distinguished panel of experts including Kiran
Anandampillai, Advisor on Technology at the National Health Authority; Dr. Neelesh Kapoor, Diabetologist and founder of Eka Care; and Dr. Pankaj Kumar,
Orthopedician. Rinkesh Shah, Head of Digital Marketing at Mankind Pharma, anchors the discussion.

Please click on the link to access the podcast: https://bit.ly/3xm6gvt

The episode provides a comprehensive
analysis of ABDM’s role in bolstering the country’s digital health
infrastructure, fostering collaboration between startups and governmental
initiatives, and elucidating the significance of digitized health records
through the ABHA platform. ABDM’s core objective is to democratize access to
healthcare technology by dismantling market monopolies and establishing robust
architectural frameworks. Through ABDM, healthcare providers can leverage
personalized data points for patients, facilitated by a suite of Personal
Health Record (PHR) apps, thus enhancing patient literacy and expediting
processes like insurance claims settlement. Notably, the incentivization of
healthcare professionals under ABDM presents a lucrative opportunity, with
doctors now eligible to earn up to Rs. 4 Crores by linking health records to
ABHA after the initial 100 records.

In the episode, Mr. Kiran Anandampillai, Advisor on Technology at the National Health
Authority
shared, “The government
created ABHA to digitize patient health records and to identify patients,
thereby enhancing interoperability among hospitals digitally. Its official
website lists partners for various end customers, along with contact
information for demos and setup assistance. Additionally, there are
approximately seven PHR apps available for patients. NHAI and IRDAI have
proposed NHCE (National Health Claims Exchange) to streamline insurance claims,
with over 22 TPAs already integrated. ABDM also features new technology for
teleconsultation through the UHI (Unified Health Interface), allowing doctors
and patients to use compatible apps
.”

During the interaction, Dr. Neelesh Kapoor, Diabetologist and
founder of Eka Care
emphasized, “Technology
is a great equalizer; it does not differentiate between people. In India, if we
look at structural problems like availability, affordability, and access, all
can be addressed by technology. It ensures good care for people residing in the
remotest areas of the country or those belonging to marginalized communities in
India
.”

Through this dedicated OTT platform for
healthcare professionals, Mankind Pharma aims to foster a culture of
knowledge-sharing and awareness-building within the medical community. By
facilitating discussions on transformative initiatives like the Ayushman Bharat
Digital Mission (ABDM), Mankind Pharma endeavors to empower healthcare professionals
with the latest insights and advancements in the field. Through Docflix®, Mankind Pharma wants to catalyze
positive change in clinical practices, enhance patient care, and drive progress
in the insurance sector, ultimately contributing to the holistic development of
India’s healthcare ecosystem.

Please click on the link to access the podcast: https://bit.ly/3xm6gvt

Powered by WPeMatico